Skip to main content

Table 3 Summary of clinically approved dual VEGFR–c-Met inhibitors

From: Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy

Drugs

Chemical structure

Target

Tumor types

Phase

Ref.

Foretinib (31)

VEGFR2/3, c-Met, Tie-2

Gastric tumor and

head/neck tumor

II

[94]

Golvatinib (32)

VEGFR2, c-Met

Head and neck tumor, liver tumor

II

[94]

Dovitinib (33)

FLT3, FGFR1/3, VEGFR1,2,3, EGFR, c-Met

Solid tumor

IV

[95]

Tivozanib (34)

VEGFR1/2/3, c-Met, PDGFR, c-Kit

Advanced renal cell

carcinoma

III

[96]

BMS-794833 (35)

VEGFR2, c-Met, Ron, Axl, FLT3

Gastric tumor

I

[93]

BMS-777607 (36)

VEGFR, c-Met, Ron, Axl,

Advanced solid tumor

II

[97]

MGCD265 (37)

VEGFR1/2, c-Met, Ron

Non-small cell lung tumor

II

[98]

AC480 (38)

VEGFR2, HER1/2/4, c-Kit, Met, Lck

Advanced solid tumor

I

[99]

CP-724714 (39)

HER2, EGFR, VEGFR2, c-Met

Advanced solid tumor

II

[100]

AMG-458 (40)

VEGFR2, c-Met

Solid tumor

Non-medicinal

[101]